Enhancing the value of medtech assets.
Based in New York and San Francisco, we fund the last mile of medical technology innovation. We invest in corporate build-to-buys and carve-outs, as well as assets that are stalled in venture and private equity portfolios. We ensure that the intellectual property is defensible; we add the productization that makes an asset manufacturable; and we create the commercial traction necessary for acquisition.
Potential buyers are identified before investment
Every investment has a corporate or private equity partner identified early in the process before we commit significant capital. No cold starts.
Clear exit path
From day one, we target a sale to that partner and — where we can — agree to terms before we close.
We back products where the science is done. We fund remaining product development, preparation for manufacturing, regulatory clearance, and validation of market demand.
Past the risky part
Who we work with
An innovation has promise but is too small for your P&L and too entangled to sell? We’ll shepherd it through development until it’s ready to rejoin the corporate balance sheet.
Corporate strategy
Need a product your core R&D budget won’t fund? We build it. You buy it.
Corporate development teams
Venture investors
A portfolio company with a cleared product and no capital to finish? We fund completion and bring it to market.
A platform investment that needs growth drivers but whose product can’t be built in-house? Our financial support and co-development partners will get the job done.